Vagus Nerve Stimulation Devices Market: Rising Prevalence of Drug-Resistant Epilepsy to Drive Market Growth to US$ 2,280.6 Million by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Vagus Nerve Stimulation Devices Market Size and Forecast (2026–2033)" forecasts how the market is set to surge 124.51% by 2033. The global vagus nerve stimulation devices market is driven by the increasing prevalence of drug-resistant epilepsy and treatment-resistant depression, growing demand for alternative neuromodulation therapies, and expanding clinical research into vagus nerve modulation. Rising awareness of implantable and non-invasive VNS therapies, coupled with growing acceptance of neuromodulation in psychiatry and neurology, is supporting adoption. Additionally, emerging applications in inflammatory and autonomic disorders are creating new growth opportunities.

The report forecasts the market to expand from US$ 1,015.8 million in 2025 to US$ 2,280.6 million by 2033, registering a robust CAGR of 10.6% over the 2026–2033 period.

Market drivers include increased use of neuromodulation as a treatment method for various neurological disorders in healthcare facilities. Neuromodulation entails using electrical signals to stimulate the vagus nerve, which in turn affects activities within the brain that control seizure occurrences, mood, and autonomic functions. The method is mainly applied in treating epilepsy and depression in cases where other forms of treatment prove to be ineffective. The growth of the market is being bolstered by the recognition of neuromodulation as a treatment method, as well as the continuous studies carried out on vagus nerve stimulation for diseases such as stroke recovery, inflammatory conditions, migraines, and post-traumatic stress disorder. The advancements made in implantable and non-invasive VNS devices have made vagus nerve stimulation therapy more accessible.

Overview of report findings

Market Growth

The vagus nerve stimulation devices market is projected to grow from US$ 1,015.8 million in 2025 to US$ 2,280.6 million by 2033, registering a compound annual growth rate (CAGR) of 10.6% between 2026 and 2033.

Key factors contributing to the growth of the vagus nerve stimulation market include the rising occurrence of drug-resistant epilepsy and depression, the rising requirement for neuromodulation, and increasing research on vagus nerve modulation. An increase in awareness regarding implantable and noninvasive treatments for vagus nerve stimulation and the growing acceptance of neuromodulation therapy in the field of neurology have also been adding momentum to the growth of the vagus nerve stimulation market.

Rising Prevalence of Drug-Resistant Epilepsy

Drug-resistant epilepsy is becoming a common reason for the growth of the vagus nerve stimulation devices market. Although antiepileptic drugs are able to suppress seizures in most cases, there are also some patients who suffer from recurring seizures even when undergoing multiple antiepileptic drugs. In this case, the application of VNS is an important supplementary way to control seizures and improve patients' health conditions. Being non-invasive as compared to resective surgery, VNS can be applied to those patients who cannot be operated on for specific reasons. Neurologists understand the importance of VNS in providing good results for their patients in the long term; thus, more patients can receive this treatment. Technical development of VNS devices is contributing to better performance, greater efficiency, and more convenient use of stimulators. Moreover, the growing incidence of epilepsy and the availability of neurology clinics promote the application of VNS as a possible therapeutic measure.

Expanding Use in Treatment-Resistant Depression

The growing use of vagus nerve stimulation for treatment-resistant depression is significantly contributing to market growth. A substantial number of patients with major depressive disorder do not achieve adequate symptom control despite multiple medication regimens and psychotherapy interventions. VNS offers an alternative neuromodulation approach that can provide long-term symptom improvement for selected patients. Increasing awareness of treatment-resistant mental health conditions and growing demand for non-pharmacological interventions are encouraging broader adoption of neuromodulation therapies within psychiatric care. Research exploring the role of vagus nerve stimulation in anxiety disorders, post-traumatic stress disorder, and other psychiatric conditions is further expanding interest in the technology. As mental health becomes a greater public health priority, healthcare providers are increasingly evaluating advanced therapeutic options beyond conventional medications. Growing clinical evidence supporting VNS therapy, combined with increasing acceptance among psychiatrists and mental health specialists, is expected to drive continued expansion of the VNS devices market over the coming years.

Geographic Insights

North America dominates the vagus nerve stimulation devices market due to high awareness of neuromodulation therapies, strong epilepsy treatment infrastructure, and early adoption of advanced neurological technologies. The region benefits from established referral networks for drug-resistant epilepsy and treatment-resistant depression. Significant clinical research activity, favorable reimbursement coverage for approved indications, and the presence of leading device manufacturers continue to support market leadership, particularly in the United States.

Europe is the second-largest VNS devices market, supported by increasing utilization of neuromodulation therapies in epilepsy management and growing recognition of treatment-resistant depression as a major healthcare challenge. The region benefits from established neurological treatment centers and ongoing clinical research evaluating new VNS applications. Strong healthcare systems and expanding physician familiarity with vagus nerve stimulation are contributing to adoption across Germany, France, the United Kingdom, Italy, and other European countries.

Asia Pacific is the fastest-growing vagus nerve stimulation devices market due to rising awareness of advanced epilepsy treatments, improving neurological care infrastructure, and increasing healthcare expenditure. Growing diagnosis rates of epilepsy and mental health disorders are expanding the potential patient population. Countries such as China, Japan, South Korea, and India are strengthening neurological and psychiatric care services, while increasing investment in specialized treatment centers is accelerating market growth throughout the region.

Market Segmentation

• By product type, the vagus nerve stimulation devices market is segmented into implantable vagus nerve stimulators and external vagus nerve stimulators. The implantable vagus nerve stimulators segment dominated the market in 2025. This is driven by their proven long-term efficacy, established clinical use, and strong adoption in treatment-resistant neurological disorders.
• Based on type, the vagus nerve stimulation devices market is segmented into invasive and noninvasive. The invasive segment dominated the market in 2025. The dominance of this segment is attributed to its superior clinical efficacy, targeted stimulation capabilities, and established use in chronic pain treatment.
• On the basis of application, the vagus nerve stimulation devices market is classified into pain & sensory modulation, functional disorders, cognitive & behavioral regulation, and other applications. The functional disorders segment dominated the market in 2025. This is driven by the increasing use of vagus nerve stimulation for epilepsy, depression, and other neurological disorders requiring long-term symptom management.
• In terms of end user, the vagus nerve stimulation devices market is categorized into hospitals, specialty clinics, ambulatory surgical centers, and other end users. The hospitals segment dominated the market in 2025. This is driven by the availability of advanced implantation facilities, skilled specialists, and comprehensive patient care services.

Competitive Strategy & Development

Key Players: The vagus nerve stimulation devices market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. electroCore, Inc.
2. SetPoint Medical
3. MicroTransponder Inc.
4. LivaNova PLC
5. Vagustim 
6. tVNS Technologies GmbH
7. Parasym Ltd
8. Soterix Medical® Inc.
9. Vielight Inc
10. AURIMOD GMBH

Trending Topics: Non-Invasive Vagus Nerve Stimulation (nVNS), Auricular Vagus Nerve Stimulation, Drug-Resistant Epilepsy Management, Treatment-Resistant Depression Therapies, Wearable VNS Devices, Home-Based Neuromodulation, VNS for Migraine Management, VNS in Stroke Rehabilitation, Bioelectronic Medicine, Closed-Loop VNS Systems, Inflammatory Disease Neuromodulation, and Digital Therapeutic Integration.

Global Headlines

• SetPoint Medical received U.S. FDA approval for its SetPoint System – In July 2025, SetPoint Medical, announced that it received U.S. FDA approval for its SetPoint System. This milestone introduced the first-ever implantable vagus nerve stimulation (VNS) device indicated for treating adults with moderate-to-severe Rheumatoid Arthritis (RA) who have failed to respond adequately to standard biologic therapies.
• Parasym launched its Nuropod non-invasive vagus nerve stimulation device – In September 2025, Parasym, announced that it launched its Nuropod non-invasive vagus nerve stimulation device. This wearable technology was clinically validated across multiple randomized studies to increase vagus nerve activity and significantly reduce systemic inflammation and chronic fatigue.

Conclusion

The global vagus nerve stimulation devices market is poised for strong growth as demand for effective treatments for drug-resistant epilepsy and treatment-resistant depression continues to rise. VNS therapy has established itself as an important neuromodulation option for patients who do not respond adequately to conventional therapies. Ongoing research into new clinical applications, including migraine, stroke rehabilitation, and inflammatory disorders, is expanding the potential scope of the market. North America remains the leading market due to its advanced neurological care ecosystem and extensive clinical adoption, while Europe benefits from strong healthcare infrastructure and growing awareness of neuromodulation therapies. Asia Pacific is expected to witness the fastest growth, supported by increasing healthcare investments and improving access to specialized care. Continued innovation and expanding clinical evidence will remain key drivers of future market development.